Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease

Sarcopenia is a significant indicator of the severity of non‐alcoholic fatty liver disease. We investigated whether sarcopenia could identify subgroups with different risk of liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) among subjects with metabolic dysfunction‐associated fatty liver disease (MAFLD).

[1]  Yuri Cho,et al.  From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? , 2021, Clinical and molecular hepatology.

[2]  A. Dhawan,et al.  NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.

[3]  H. Jung.  Statin use and outcome risks according to predicted CVD risk in Korea: A retrospective cohort study , 2021, PloS one.

[4]  Li Jin,et al.  The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease related genetic variants. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  Yong‐ho Lee,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  Donghee Kim,et al.  Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease , 2020, Clinical and molecular hepatology.

[7]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[8]  T. Kawaguchi,et al.  MAFLD identifies patients with significant hepatic fibrosis better than NAFLD , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[9]  A. Sanyal,et al.  The times they are a-changin' (for NAFLD as well). , 2020, Journal of hepatology.

[10]  Michael T. Lu,et al.  Association of Hepatic Steatosis with Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  Jiaofeng Huang,et al.  Comparison of MAFLD and NAFLD diagnostic criteria in real world , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[12]  K. Corey,et al.  Advanced fibrosis is associated with incident cardiovascular disease in patients with non‐alcoholic fatty liver disease , 2020, Alimentary pharmacology & therapeutics.

[13]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[14]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[15]  Stephan von Haehling,et al.  Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015 , 2015, Journal of cachexia, sarcopenia and muscle.

[16]  Chaohui Yu,et al.  Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis , 2019, Hepatology International.

[17]  B. Cha,et al.  Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B , 2018, Alimentary pharmacology & therapeutics.

[18]  S. Basu,et al.  Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk , 2018, Annals of Internal Medicine.

[19]  L. Castéra.  Diagnosis of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: Non‐invasive tests are enough , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[20]  Q. Xiao,et al.  The Common Mechanisms of Sarcopenia and NAFLD , 2017, BioMed research international.

[21]  A. Allen,et al.  Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis , 2017, Hepatology.

[22]  G. Marchesini,et al.  Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease , 2017, Alimentary pharmacology & therapeutics.

[23]  M. Chang,et al.  Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. , 2017, Journal of hepatology.

[24]  Xueli Yang,et al.  Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China) , 2016, Circulation.

[25]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[26]  D. Jun,et al.  Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment , 2016, Clinical and molecular hepatology.

[27]  Y. Khang,et al.  Data Resource Profile: The Korea Youth Risk Behavior Web-based Survey (KYRBS). , 2016, International journal of epidemiology.

[28]  Randi E. Foraker,et al.  VALIDATION OF THE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) POOLED COHORT RISK EQUATIONS BY EDUCATION LEVEL: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY , 2016 .

[29]  E. Kang,et al.  Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011) , 2016, Hepatology.

[30]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[31]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[32]  H. Bang,et al.  Non–Laboratory-Based Self-Assessment Screening Score for Non-Alcoholic Fatty Liver Disease: Development, Validation and Comparison with Other Scores , 2014, PloS one.

[33]  Jo Eun Kim,et al.  The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture: results from the KNHANES 2008-2011. , 2014, The Journal of clinical endocrinology and metabolism.

[34]  Mary Cushman,et al.  Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. , 2014, JAMA.

[35]  Maren S Fragala,et al.  The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[36]  Jennifer G. Robinson,et al.  Reply: 2013 ACC/AHA guideline on the assessment of cardiovascular risk. , 2014, Journal of the American College of Cardiology.

[37]  A. Sanyal,et al.  USE OF THE FIB4 INDEX FOR NON-INVASIVE EVALUATION OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE , 2011 .

[38]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[39]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[40]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[41]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[42]  E Davio,et al.  The times they are a'changin'. , 1970, The Journal of practical nursing.